Pharmafile Logo
Pharmafocus logo
Advanced Search

sofosbuvir

Showing 15 posts of 28 posts found.

gilead-sciences

Gilead receives EU approval for combo hepatitis C treatment

July 11, 2016
Sales and Marketing Epclusa, Gilead, eu approval, sofosbuvir

Gilead Sciences (NASDAQ: GILD) has received a marketing authorisation approval from the European Commission for combination treatment Epclusa (sofosbuvir/velpatasvir) for …

News
gilead-sciences

Gilead presents data highlighting progress and efficacy in liver and hepatitis C therapies

April 20, 2016
Research and Development, Sales and Marketing Gilead, harvoni, hepatitis, liver, sofosbuvir

Gilead (NASDAQ: GILD) has presented a broad range of results on its current and potential therapeutics at the International Liver …

News
sovaldi-web

Federal jury rules in MSD’s favour in Gilead blockbuster hepatitis C drug dispute

March 23, 2016
Medical Communications, Research and Development Gilead, MSD, blockbuster, federal court, federal jury, hit, patents, sales, sales hit, sofosbuvir, sovaldi

Gilead’s dominance of the hepatitis C market is under severe threat after a federal jury ruled in favour of MSD …

News
Sovaldi bottle

Gilead’s Sovaldi wins Drug Discovery of the Year Award

December 16, 2015
Research and Development British Pharmacological Society, Gilead, Gilead Sciences, hepatitis C, sofosbuvir, sovaldi

Gilead Science’s hepatitis C treatment Sovaldi has been awarded the British Pharmacological Society’s prestigious Drug Discovery of the Year 2016. …

News
FDA image

FDA sued over failure to disclose Sovaldi data

June 30, 2015
Sales and Marketing FDA, Gilead, hepatitis C, sofosbuvir, sovaldi

Two groups that campaign for wider access to medicines have filed a lawsuit against the FDA, in a bid to …

News
Sovaldi image

China rejects Gilead’s Sovaldi patent

June 24, 2015
Research and Development, Sales and Marketing China, Gilead, hep C, sofosbuvir, sovaldi

Manufacturer of the blockbuster hepatitis C treatment Sovaldi Gilead has seen its application for a patent in China rejected following …

News
pillsphotos1

The Pharmafocus debate: Is the price of new hepatitis C treatments fair?

April 27, 2015
Research and Development, Sales and Marketing Doctors of the World, Drug pricing, EFPIA, Gilead, MSF, drug cost, hepatitis C, patents, sofosbuvir, sovaldi

YES – says Richard Bergström, director general of the European Federation of Pharmaceutical Industries and Associations (EFPIA), who argues that …

Feature
Gilead image

Gilead presents new Sovaldi data

April 23, 2015
Sales and Marketing GS-5816, GS-9857, Gilead, NS3/4A, SVR12, hepatitis C, sofosbuvir, sovaldi

Gilead is looking to several new studies to support future new Sovaldi combinations and broadened treatment groups for its hepatitis …

News
Sovaldi image

$10 generic Solvaldi emerges in Bangladesh

March 10, 2015
Manufacturing and Production, Sales and Marketing Gilead, World Trade Organization, hep C, incepta, sofosbuvir, sofosbuvir), sovaldi

A Bangladeshi pharma company is producing an unlicensed generic version of Gilead’s hepatitis C drug Sovaldi for $10 per pill …

News
Sovaldi image

Gilead frustrated despite final NICE Sovaldi nod

February 25, 2015
Sales and Marketing Gilead, NHS, NICE, hep C, hepatitis, sofosbuvir, sovaldi

NICE has published final guidance confirming its approval of Gilead’s controversial blockbuster hepatitis C treatment Sovaldi – but Gilead and …

News
Biogen image

Pharma is boosting pipelines to avoid patent cliff

February 11, 2015
Sales and Marketing Biogen IDEC, Moody's, dimethyl fumarate, lilly, pharma, pipelines, sofosbuvir, sovaldi, tecfidera

Pharmaceutical companies have improved their pipelines of new drugs over the last 18 months according to financial analysts Moody’s Investors …

News
Doctors image

Charity challenges Sovaldi patent

February 10, 2015
Sales and Marketing Gilead, HCV, Médecins du Monde, sofosbuvir, sovaldi, world health organization

Doctors of the World (also known as Médecins du Monde) has filed an opposition to the patent for Gilead’s blockbuster …

News
FDA image

Pharma adverse event FDA reports are inadequate

February 5, 2015
Sales and Marketing FDA, Gilead, Solvaldi, US Institute for Safe Medication Practices, pharma, sofosbuvir

Reports of adverse drug events submitted to the FDA by pharma firms are often incomplete and lacking in detail, a …

News
Gilead image

Gilead sales soar on back of hepatitis drugs

February 4, 2015
Sales and Marketing Atripla, Gilead, efavirenz, emtricitabine, harvoni, lepidasvir, q4, sofosbuvir, sovaldi, tenofovi

The new blockbuster hepatitis C treatments Sovaldi and Harvoni more than doubled Gilead’s sales in the last quarter of 2014 …

News
Gilead image

New drug added to generic Sovaldi licensing

January 26, 2015
Manufacturing and Production, Sales and Marketing Gilead, HCV, hepatitis C, sofosbuvir, sovaldi

Gilead has expanded the licensing of generic versions of its blockbuster hepatitis C treatment Sovaldi to include a new experimental …

News
The Gateway to Local Adoption Series

Latest content

STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025

Norgine enters exclusive licensing agreement with Vir Biotechnology

December 18, 2025

Incyclix appoints Kimberly Blackwell to Board of Directors

December 17, 2025

Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International

December 17, 2025

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025